POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.

承包商将根据FDA的要求开发生物剂量测定设备，以应对RAD-NUC事件。 第一反应者社区最迫切的需求之一是对受影响的人口进行快速分类，以便为受害者提供适当和有限的护理，以管理急性呼吸道综合征。为了应对这一对我们国家安全的紧迫风险，承包商建议开发一种基于循环miRNA的组织特异性辐射生物剂量计（miDOS）。

The contractor, in pursuit of licensure and in accordance with the FDA, will develop a biodosimetry device in response to a RAD-NUC incident. One of the most urgent needs of the first responder community is to perform rapid triage of the affected population in order to match victims with appropriate and limited care available to manage for ARS.2. In response to this urgent risk to our national security, the contractor proposes to develop a circulating miRNA based tissue specific radiation biodosimeter (miDOS).